Dedifferentiated liposarcoma
MONDO:0020563A high-grade subtype of liposarcoma (LS) that progresses from well-differentiated liposarcoma (WDLS), and most often occurs in the retroperitoneum. It is defined as a region of nonlipogenic sarcoma associated with WDLS.
Also known as: DDLPS, DDLS, dedifferentiated liposarcoma
2855 clinical trials for this condition and its sub-types, 37 tagged with Dedifferentiated liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a new drug boost chemotherapy against rare sarcomas?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called DT-7012 to standard chemotherapy (doxorubicin) helps people with advanced soft tissue sarcoma, specifically two subtypes: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Participants receive either…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Nanoparticles join radiation to fight rare cancer recurrence
Disease control Not yet recruitingThis early-phase study tests whether injecting tiny tantalum particles directly into a recurrent soft tissue sarcoma tumor, followed by radiation, is safe and tolerable. Nine adults with a specific type of sarcoma that has come back after standard treatment will receive one of th…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug combo takes on rare sarcomas
Disease control Not yet recruitingThis early-phase trial tests a new drug called BOLD-100 combined with standard chemotherapy (doxorubicin) in 32 people with advanced soft tissue sarcomas that cannot be removed by surgery or have spread. The goal is to find the safest dose and see if the combination can shrink tu…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC